Version history

{
  "session_id": "sess-hyp-0bb6b3633d42",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: TREM2 as a Therapeutic Target in Late-Stage Alzheimer's Disease\n\n## Executive Summary\n\nThis hypothesis proposes a stage-specific model where TREM2 downregulation in late-stage AD represents a critical inflection point for microglial maladaptation. While TREM2 is a well-validated and druggable target with active clinical development, the specific mechanistic claim requires careful scrutiny.\n\n---\n\n## Target Druggability Assessment\n\n**TREM2 is a highly druggable target.** Key attributes:\n\n| Property | Assessment |\n|----------|------------|\n| **Target Class** | Cell-surface receptor (type-1 transmembrane, Ig superfamily) |\n| **Genetic Validation** | Strong—",
  "tokens_used": "171",
  "persona_id": "persona-domain_expert"
}